Liprolog

Insulin lispro, the active ingredient in Liprolog, is a rapid‑acting insulin analog presented as a solution for injection for subcutaneous and intravenous use. It treats type 1 and type 2 diabetes mellitus by quickly lowering blood glucose levels after meals.

GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products and reliable cold‑chain logistics for injectable medicines. Our distribution network complies with EU regulations and supports timely delivery to diverse healthcare settings.

Liprolog (insulin lispro) is used to achieve rapid glucose control in diabetes management.

Type 1 diabetes mellitus: provides fast post‑prandial glucose reduction to match insulin needs. Type 2 diabetes mellitus: offers rapid glucose lowering when oral agents are insufficient or during insulin initiation. Insulin pump therapy (continuous subcutaneous insulin infusion): serves as a rapid‑acting bolus insulin for precise dosing.

The most frequently reported adverse reactions with Liprolog are related to its pharmacologic action and injection site.

Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glycemic control. - Lipodystrophy: localized changes in fat tissue from repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin antibodies: may reduce insulin effectiveness or cause resistance.

When using Liprolog, clinicians should consider several safety measures to minimize risks.

Dose adjustment: tailor the dose based on frequent blood‑glucose monitoring and individual response. Hypoglycemia risk: educate patients to recognize symptoms and keep fast‑acting carbohydrates available. Renal impairment: monitor kidney function and adjust dosage as reduced clearance may increase hypoglycemia risk. Pregnancy and lactation: use only if benefits outweigh potential risks and under specialist supervision. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin lispro may interact with other medicines, altering its glucose‑lowering effect or increasing adverse events.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycemia symptoms, making detection harder. - Monoamine oxidase inhibitors (MAOIs): may potentiate insulin’s glucose‑lowering action.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents (e.g., sulfonylureas): combined use raises hypoglycemia risk. - Glucocorticoids: may increase insulin requirements due to elevated blood glucose. - Thyroid hormones: can modify glucose metabolism and affect insulin dosing.